The mechanistic detail in the model can facilitate modeling-based investigations of both specific immunomodulatory interventions that have been in explored in COVID-19 patients, such as the IL-6 inhibitors (e.g., tocilizumab, sarilumab)50,57, JAK inhibitors (e.g., tofacitinib, baricitinib)58 as well as broader immunosuppressive agents such as corticosteroids59. The gene discussed is IL6; the disease is COVID-19.